Baker Bros. Advisors LP Tcr2 Therapeutics Inc. Transaction History

Baker Bros. Advisors LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	BUY	$4.58 - $8.34 $2.64 Million - $4.81 Million	576,603 Added 326.76%	753,064 $3.51 Million
Q1 2021 May 17, 2021	BUY	$20.38 - $34.07 $1.34 Million - $2.23 Million	65,573 Added 59.13%	176,461 $3.9 Million
Q4 2020 Feb 16, 2021	SELL	$19.0 - $32.63 $221,236 - $379,943	-11,644 Reduced 9.5%	110,888 $3.43 Million
Q3 2020 Nov 16, 2020	BUY	$13.1 - $20.69 $1.61 Million - $2.54 Million	122,532 New	122,532 $2.49 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.